Sandoz voluntarily recalls 24 lots of injectable methotrexate

10/27/2010 | Reuters

Novartis' Sandoz unit is recalling 24 lots of methotrexate, an injectable chemotherapy drug, after discovering glass particulates in the product. The recall affects vials of 50 milligrams per 2 milliliters and 250 milligrams per 10 milliliters. Sandoz has not received reports of adverse effects concerning the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA